Large-scale proteomics analysis of human ovarian cancer for biomarkers.
Ovarian cancer is usually found at a late stage when the prognosis is often bad. Relative survival rates decrease with tumor stage or grade, and the 5-year survival rate for women with carcinoma is only 38%. Thus, there is a great need to find biomarkers that can be used to carry out routine screening, especially in high-risk patient groups. Here, we present a large-scale study of 64 tissue samples taken from patients at all stages and show that we can identify statistically valid markers using nonsupervised methods that distinguish between normal, benign, borderline, and malignant tissue. We have identified 217 of the significantly changing protein spots. We are expressing and raising antibodies to 35 of these. Currently, we have validated 5 of these antibodies for use in immunohistochemical analysis using tissue microarrays of healthy and diseased ovarian, as well as other, human tissues.
Bengtsson
Sofia
S
Department of Protein Technology, Lund University, 221 84 Lund, Sweden.
Krogh
Morten
M
Szigyarto
Cristina Al-Khalili
CA
Uhlen
Mathias
M
Schedvins
Kjell
K
Silfverswärd
Claes
C
Linder
Stig
S
Auer
Gert
G
Alaiya
Ayodele
A
James
Peter
P
D000906:Antibodies / Q000276:immunology; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000276:immunology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D009363:Neoplasm Proteins / Q000032:analysis* / Q000276:immunology; D010051:Ovarian Neoplasms / Q000737:chemistry / Q000175:diagnosis* / Q000473:pathology; D040901:Proteomics
D000906:Antibodies; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins